Preparation and Evaluation of Candesartan Cilexetil Solid Supersaturated Self-nanoemulsion Containing Phospholipids

Candesartan cilexetil (CC) suffers from poor solubility, first-pass effect, and low bioavailability. In order to solve these problems, a solid supersaturated self-nanoemulsifying drug delivery system containing phospholipids (solid PC-S-SNEDDS) was constructed in this study. The system was based on the traditional self-nanoemulsifying drug delivery system (SNEDDS) with the addition of precipitation inhibitors, phospholipids and solid carriers to inhibit crystallisation, increase lymphatic transport, and facilitate transport and storage. SNEDDS, supersaturated self-nanoemulsifying drug delivery system (S-SNEDDS), supersaturated self-nanoemulsifying drug delivery system containing phospholipids (PC-S-SNEDDS), and solid PC-S-SNEDDS were prepared by central composite design and single factor investigation. The spectra of PXRD and FT-IR showed that the drugs in the solid PC-S-SNEDDS existed in an amorphous or molecular form and did not form new chemical bonds with the excipients. The results of dissolution experiments showed that compared with CC and marketed capsules, the four self-nanoemulsions could significantly increase the dissolution rate and cumulative dissolution of CC. The stability results demonstrate that the stability of the PC-S-SNEDDS was improved after curing. The results of pharmacokinetics in rats showed that the bioavailability of solid PC-S-SNEDDS was 568.17% and 415.00% of CC suspension and marketed capsules. In the lymphatic transport experiment, compared with CC suspension, solid PC-S-SNEDDS increased the proportion of lymphatic transport from 18.69% to 62.14%. The results showed that solid PC-S-SNEDDS improved the solubility, reduced the first-pass effect, and greatly improved the bioavailability of CC, which was a promising drug delivery system to solve the problem of CC.